[CAS NO. 81110-73-8] Racecadotril
PRODUCTS SPECIFICATIONS [81110-73-8]
DESCRIPTION [81110-73-8]
Overview
| MDL | MFCD00865520 |
|---|---|
| Molecular Weight | 385.48 |
| Molecular Formula | C21H23NO4S |
| SMILES | O=C(OCC1=CC=CC=C1)CNC(C(CSC(C)=O)CC2=CC=CC=C2)=O |
Summary
Racecadotril (Acetorphan) is a neutral endopeptidase ( NEP ) inhibitor. Racecadotril and its active metabolite Thiorphan inhibits purified NEP activity from mouse brain with K i s of 4500 and 6.1 nM, , respectively. Antidiarrheal agent [1] .
In Vivo
In mice, following i.v. administration, Racecadotril is rapidly metabolized to Thiorphan; thus, 30 min after the injection only Thiorphan is recovered from the kidney whereas the parent compound Racecadotril is not detected
[1]
.
In rats 92% of a single-dose (10 mg/kg) of radioactively labeled Racecadotril is eliminated within 24 h
[1]
.
Racecadotril is a neutral endopeptidase (NEP) inhibitor with known antidiarrheal activity in animals. Orally administered Racecadotril (100 mg/kg ) shows efficacy in a rat model of castor oil-induced diarrhea
[2]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | 6-to-7-week-old male Wistar rats [2] |
| Dosage: | 100 mg/kg |
| Administration: | A single oral treatment; 30 minutes before castor oil administration. |
| Result: | Significantly reduced stool output but did not prevent the occurrence of diarrhea (100% incidence). |
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT01302093 | McNeil AB|Johnson & Johnson Consumer and Personal Products Worldwide |
Antidiarrheals
|
January 2011 | Phase 1 |
| NCT05216822 | Assiut University |
Acute Watery Diarrhea
|
June 1, 2018 | Phase 1 |
| NCT03463512 | Abbott |
Diarrhea
|
March 29, 2018 | Phase 3 |
| NCT01153854 | National Institute of Pediatrics, Mexico|Ferrer Laboratories |
Diarrhea
|
January 2007 | Phase 3 |
| NCT05600062 | Queen Mary University of London|Medical Research Council |
Acute Respiratory Distress Syndrome
|
January 16, 2023 | Not Applicable |
| NCT01476683 | McNeil AB|Johnson & Johnson Consumer and Personal Products Worldwide |
Diarrhea
|
December 2011 | Phase 1 |
| NCT01948011 | Bioprojet |
Healthy Male Volunteers
|
September 2013 | Phase 1 |
| NCT03473561 | Abbott |
Diarrhea, Infantile
|
August 25, 2018 | Phase 3 |
| NCT04885049 | Shaheed Zulfiqar Ali Bhutto Medical University |
Diarrhea
|
September 1, 2021 | Not Applicable |
| NCT01577043 | Centro Pediatrico Albina de Patino |
Acute Diarrhea|Acute Gastroenteritis
|
September 2011 | Phase 4 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : ≥ 100 mg/mL ( 259.42 mM )
* "≥" means soluble, but saturation unknown.
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.5942 mL | 12.9708 mL | 25.9417 mL |
| 5 mM | 0.5188 mL | 2.5942 mL | 5.1883 mL |
| 10 mM | 0.2594 mL | 1.2971 mL | 2.5942 mL |
References
- [1] Marion Eberlin, et al. A comprehensive review of the pharmacodynamics, pharmacokinetics, and clinical effects of the neutral endopeptidase inhibitor Racecadotril. Front Pharmacol. 2012 May 30;3:93.
- [2] David W Griggs, et al. Pharmacologic Comparison of Clinical Neutral Endopeptidase Inhibitors in a Rat Model of Acute Secretory Diarrhea. J Pharmacol Exp Ther. 2016 May;357(2):423-31.
Synonyms